|Bid||1.4500 x 1100|
|Ask||1.4600 x 3000|
|Day's Range||1.4300 - 1.5050|
|52 Week Range||0.1850 - 4.4700|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Registration link for webcast appears belowSAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, will be aired during an investor webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021, the Company granted nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 1 and nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 2.
Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the US FDA for SBS)Merger of Napo EU & Dragon SPAC expected to be effective within approximately 80 days, with related future SBS license and milestone fees totaling up to $12.5 millionMILAN, ITALY and SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2021 / Dragon SPAC S.